Abstract: A system to provide flexible stimulation pattern definition, delivery, and control to dynamically adjust a therapy regimen for electrical stimulation therapy based on patient needs. Firmware in an electrical stimulation delivery device that executes the therapy regimen may be implemented as a “player” of a series of instructions for the received stimulation patterns. The system may include a wearable device or an implantable device. An external computing device configured to program the electrical stimulation delivery device may include a stimulation pattern construct collection from which a clinician can select, assemble, and modify waveforms, bursts, pattern, sensing or other event triggers etc. to create a therapy regimen. The external computing device may transmit software that defines the selected regimen to the electrical stimulation delivery device memory, where the device “plays” the instructions to deliver electrical stimulation according to the therapy regimen.

Abstract: An example system includes stimulation generation circuitry configured to deliver electrical stimulation to a patient; sensing circuitry configured to sense one or more biomarker signals; and processing circuitry configured to: cause delivery of electrical stimulation with the patient in a first patient state; receive a first instance of a biomarker signal in presence of the electrical stimulation with the patient in the first patient state; cause delivery of electrical stimulation with the patient in a second patient state; receive a second instance of the biomarker signal in presence of the electrical stimulation with the patient in the second patient state; determine whether a difference between the first instance of the biomarker signal and the second instance of the biomarker signal satisfies a threshold; select a therapy mode based on whether the difference satisfies the threshold; and cause delivery of electrical stimulation in accordance with the selected therapy mode.

Abstract: An example method includes determining, by an implantable medical device (IMD), an electrode of a plurality of electrodes of a lead to be used to deliver electrical stimulation to a patient at a particular time; selecting, by the IMD and based on the determined electrode, a set of electrodes of the plurality of electrodes; and sensing, by the IMD and via the selected set of electrodes, electrical signals of the patient at the particular time.

Abstract: Devices, systems, and techniques are described for transitioning between different groups of electrical stimulation programs. For example, a system may control delivery of second electrical stimulation defined by one or more second programs of a second group of stimulation programs on a time-interleaved basis with first electrical stimulation defined by one or more first programs of the first group of stimulation programs. The system may change a first ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a first period of time to a second ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a second period of time.

Abstract: In some examples of selecting a target therapy delivery site for treating a patient condition, a relatively high frequency electrical stimulation signal is delivered to at least two areas within a first region (e.g., an anterior nucleus of the thalamus) of a brain of a patient, and changes in brain activity (e.g., as indicated by bioelectrical brain signals) within a second region (e.g., a hippocampus) of the brain of the patient in response to the delivered stimulation are determined. The target therapy delivery site, an electrode combination, or both, may be selected based on the changes in brain activity.

Abstract: In some examples of selecting a target therapy delivery site for treating a patient condition, a relatively high frequency electrical stimulation signal is delivered to at least two areas within a first region (e.g., an anterior nucleus of the thalamus) of a brain of a patient, and changes in brain activity (e.g., as indicated by bioelectrical brain signals) within a second region (e.g., a hippocampus) of the brain of the patient in response to the delivered stimulation are determined. The target therapy delivery site, an electrode combination, or both, may be selected based on the changes in brain activity.

Abstract: A medical device or system of medical devices can be configured to detect an indicator of a symptom in a patient; in response to detecting the indicator of the symptom in the patient, deliver to the patient a first stimulation therapy; and in response to determining that the indicator of the symptom has been present for more than a threshold amount of time after beginning to deliver the first stimulation therapy a second stimulation therapy different than the first stimulation therapy.

Abstract: The disclosure describes a method and system or controlling symptoms of patients suffering from Parkinson's Disease. In some examples, one or more biomarkers indicative of a patient's present symptoms are determined. The biomarkers may be used to control therapy delivered to the patient in a closed-loop manner. In addition, biomarkers may be used as an indication of therapy effectiveness.

Abstract: Devices, systems, and techniques are described for transitioning between different groups of electrical stimulation programs. For example, a system may control delivery of second electrical stimulation defined by one or more second programs of a second group of stimulation programs on a time-interleaved basis with first electrical stimulation defined by one or more first programs of the first group of stimulation programs. The system may change a first ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a first period of time to a second ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a second period of time.

Abstract: The disclosure describes a method and system or controlling symptoms of patients suffering from Parkinson's Disease. In some examples, one or more biomarkers indicative of a patient's present symptoms are determined. The biomarkers may be used to control therapy delivered to the patient in a closed-loop manner. In addition, biomarkers may be used as an indication of therapy effectiveness.

Abstract: The disclosure describes a method and system or controlling symptoms of patients suffering from Parkinson's Disease. In some examples, one or more biomarkers indicative of a patient's present symptoms are determined. The biomarkers may be used to control therapy delivered to the patient in a closed-loop manner. In addition, biomarkers may be used as an indication of therapy effectiveness.

Abstract: In some examples of selecting a target therapy delivery site for treating a patient condition, a relatively high frequency electrical stimulation signal is delivered to at least two areas within a first region (e.g., an anterior nucleus of the thalamus) of a brain of a patient, and changes in brain activity (e.g., as indicated by bioelectrical brain signals) within a second region (e.g., a hippocampus) of the brain of the patient in response to the delivered stimulation are determined. The target therapy delivery site, an electrode combination, or both, may be selected based on the changes in brain activity.

Abstract: Various embodiments concern identifying a biomarker in the presence of electrical stimulation. Various embodiments concern delivering electrical stimulation to a patient and sensing one or more signals while the electrical stimulation is being delivered, the one or more signals including data indicative of physiological activity. Various embodiments further include determining an intensity of the electrical stimulation and determining whether the data indicates the presence of a biomarker based on a variable threshold, the variable threshold being variable based on the intensity of the electrical stimulation. Various embodiments concern determining a relationship between stimulation intensity and a biomarker parameter to determine the variability of the variable threshold.

Abstract: This disclosure describes techniques for controlling spectral aggressors in a sensing device that uses a chopper amplifier to amplify an input signal prior to sampling the signal. In some examples, the techniques for controlling spectral aggressors may include generating a chopper-stabilized amplified version of an input signal based on a chopper frequency, sampling the chopper-stabilized amplified version of the input signal at a sampling rate to generate a sampled signal, and analyzing a target frequency band of the sampled signal. The chopper frequency and the sampling rate may cause spectral interference that is generated due to the chopper frequency to occur in the sampled signal at one or more frequencies that are outside of the target frequency band of the sampled signal. The techniques for controlling spectral aggressors may reduce the noise caused by the chopper frequency in the resulting sampled signal, thereby improving the quality of the signal.

Abstract: This disclosure describes techniques for controlling spectral aggressors in a sensing device that uses a low power sleep mode to manage the power consumed by the device. In some examples, the techniques for controlling spectral aggressors may include configuring one or more of an algorithm processing rate for a processor, a buffering rate for the processor, a sampling rate for an analog-to-digital converter, an execution unit processing rate for the processor, and an algorithm subdivision factor for the processor such that spectral interference caused by a sleep cycle rate of the processor occurs outside of one or more target frequency bands of a sampled signal. The techniques of this disclosure may be used to reduce noise in a sensing system that uses a low power sleep mode to manage the power consumed by the device.

Abstract: The disclosure describes a method and system or controlling symptoms of patients suffering from Parkinson's Disease. In some examples, one or more biomarkers indicative of a patient's present symptoms are determined. The biomarkers may be used to control therapy delivered to the patient in a closed-loop manner. In addition, biomarkers may be used as an indication of therapy effectiveness.

Abstract: This disclosure describes a state machine framework for programming closed-loop algorithms that control the delivery of therapy to a patient by an implantable medical device (IMD). The state machine framework may use one or more programmable state parameters to define at least part of a structure of a state machine that generates one or more therapy decisions based on one or more sensed states of the patient. The state machine framework may include a state machine runtime environment that executes on an IMD and that is configurable to implement a variety of different state machines depending on programmable state parameters that are received from an external device. The techniques of this disclosure may, in some cases, allow IMD developers and/or users to program, change, and/or download new closed-loop control policy algorithms during the lifespan of the IMD without requiring new firmware code to be downloaded onto the IMD.

Abstract: This disclosure describes a state machine framework for programming closed-loop algorithms that control the delivery of therapy to a patient by an implantable medical device (IMD). The state machine framework may use one or more programmable state parameters to define at least part of a structure of a state machine that generates one or more therapy decisions based on one or more sensed states of the patient. The state machine framework may include a state machine runtime environment that executes on an IMD and that is configurable to implement a variety of different state machines depending on programmable state parameters that are received from an external device. The techniques of this disclosure may, in some cases, allow IMD developers and/or users to program, change, and/or download new closed-loop control policy algorithms during the lifespan of the IMD without requiring new firmware code to be downloaded onto the IMD.

Abstract: This disclosure describes techniques for controlling spectral aggressors in a sensing device that uses a low power sleep mode to manage the power consumed by the device. In some examples, the techniques for controlling spectral aggressors may include configuring one or more of an algorithm processing rate for a processor, a buffering rate for the processor, a sampling rate for an analog-to-digital converter, an execution unit processing rate for the processor, and an algorithm subdivision factor for the processor such that spectral interference caused by a sleep cycle rate of the processor occurs outside of one or more target frequency bands of a sampled signal. The techniques of this disclosure may be used to reduce noise in a sensing system that uses a low power sleep mode to manage the power consumed by the device.

Abstract: This disclosure describes techniques for controlling spectral aggressors in a sensing device that uses a chopper amplifier to amplify an input signal prior to sampling the signal. In some examples, the techniques for controlling spectral aggressors may include generating a chopper-stabilized amplified version of an input signal based on a chopper frequency, sampling the chopper-stabilized amplified version of the input signal at a sampling rate to generate a sampled signal, and analyzing a target frequency band of the sampled signal. The chopper frequency and the sampling rate may cause spectral interference that is generated due to the chopper frequency to occur in the sampled signal at one or more frequencies that are outside of the target frequency band of the sampled signal. The techniques for controlling spectral aggressors may reduce the noise caused by the chopper frequency in the resulting sampled signal, thereby improving the quality of the signal.